ulcerative colitis

[Stem Cell Research & Therapy] The authors review the recent research advances of therapies based on the mesenchymal stem cells-Exo for treating ulcerative colitis and colorectal cancer.

[Morphic Therapeutic] Morphic Therapeutic announced the initiation of MORF-057-201, the EMERALD-1 study, a Phase IIa trial of MORF-057 in patients with moderate to severe ulcerative colitis.

[Pfizer, Inc.] Pfizer, Inc. announced positive topline results from a Phase III study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate receptor modulator in development for the treatment of moderately to severely active ulcerative colitis.

[Histology and Histopathology] To elucidate tumor cell behavior associated with CSC marker expression, the expression of CD133, CD44v9, and ALDH1A1, which are considered markers of CSCs, was examined in sporadic and ulcerative colitis-associated colorectal tumors.

[Cell Death Discovery] Within LPS-treated MODE-K cells, METTL3 knockdown promoted cell viability, inhibited cell apoptosis, decreased apoptotic caspase3/9 cleavage, and decreased the levels of proinflammatory cytokines and inflammatory enzymes

[Nature Reviews Gastroenterology & Hepatology] Scientists summarizes the critical mediators and mechanisms involved in immune cell trafficking in IBD and the available evidence for efficacy, safety and pharmacokinetics of sphingosine 1-phosphate receptor modulators in IBD and other immune-mediated disorders.